PMCPA Case Library

1,752 PMCPA Rulings.
Every One Analysed.

The only structured, searchable PMCPA case library in the UK. Expert video walkthroughs, podcast episodes, and MCQ assessments on every ruling — so you understand why companies breach the Code, not just that they did.

▶ Video analysis per case
🎧 Podcast per case
✍ MCQ + CPD certificate
🔒 From £299/year
1752+
Case Studies
5 min
Per Video
5 pts
Per Case Passed
8
Themes
📚
Subscribe for full case library access
Read free summaries below, or subscribe to unlock expert video walkthroughs, podcast audio and CPD certificates.
Sign in See plans ↓
Free — Browsing
✓ Browse all 1752+ case titles
✓ Filter by theme & therapy area
✓ See case reference, company & outcome
✗ Search by company or clause
✗ Video walkthroughs
✗ Podcast episodes
✗ MCQ assessments & CPD certificates
Subscribed — Full Access
✓ Search by company, clause & case ref
✓ Expert video walkthrough per case
✓ Podcast episode per case
✓ MCQ quiz — 5 CPD points per pass
✓ Personalised CPD completion certificate
✓ New cases added monthly
Subscribe from £299/year →
Search by company, clause, case reference... 🔒
All (1752) Social Media & Digital (720) HCP Hospitality & Meetings (431) Data & Publications (321) Off-label Promotion (219) Patient Organisations (44) Transfers of Value (9) Promotional Material (4) Samples & Gifts (2)
Therapy Area: All areas Other (360) Oncology (218) Cardiovascular (189) Respiratory (178) CNS & Neurology (169) Infectious Diseases (115) Diabetes (114) Rare Diseases (104) Immunology & Rheumatology (84) Dermatology (67) Obesity & Weight Management (63) Musculoskeletal & Bone (60) Ophthalmology (31)
Showing 36 results · Social Media & Digital · Diabetes  · Clear
🔒 Subscribers only
AUTH/3906/5/24
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Boehringer Ingelheim
An anonymous complainant found a Jardiance (empagliflozin) case-study slide deck (“Weight and type 2 diabetes”) accessible via a URL on a Boehringer promotional website.The deck appeared to hav…
Clauses: NONE
2024 🔒 Subscribe
🔒 Subscribers only
AUTH/3846/11/23
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
AstraZeneca breached Clauses 6.1 and 5.1 after Calquence dosing leaflet omitted monitoring caveat fo
An anonymous, contactable health professional complained about an 8-page Calquence (acalabrutinib) tablet dosing resource (GB-48523; date of preparation September 2023).Page 4 stated: “No dose ad…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3832/10/23
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
AstraZeneca CKD education video on SGLT2 inhibitors
An anonymous, contactable complainant challenged a ~19-minute AstraZeneca-hosted video, “Chronic Kidney Disease Management Made Simple”, on AstraZeneca’s medical platform website.The video fe…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3853/11/23
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
A. Menarini breached Clause 26.1 after third-party X post showed “Invokana canagliflozin tablets” at
A member of the public complained about an X (formerly Twitter) post showing a panoramic photo of a diabetes conference exhibition hall.In the foreground, A. Menarini’s exhibition stand was visib…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3684/8/22
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Bayer breached ABPI Code after US Kerendia DTC
A contactable complainant (healthcare communications agency employee) complained about a Kerendia (finerenone) banner advertisement appearing on MailOnline (a UK news website with a .co.uk URL).The…
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3601/1/22
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Boehringer Ingelheim
A concerned health professional complained about a dynamic digital banner advertisement for Trajenta (linagliptin) by Boehringer Ingelheim Limited.The banner included the claim: “Unique convenien…
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3599/1/22
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
AstraZeneca employee’s LinkedIn ‘like’ and comment held to be POM advertising to the public (AUTH/35
A hospital consultant complained about two LinkedIn items involving an AstraZeneca employee: (1) the employee’s own post about a blood pressure (BP) study; and (2) the employee ‘liking’ and c…
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3661/6/22
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
AstraZeneca breached Clause 8.1 over Forxiga website certification differences between desktop and m
An anonymous, contactable health professional complained about certification of the Forxiga (dapagliflozin) diabetes webpage on www.forxiga.co.uk.The complainant alleged the desktop and mobile vers…
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3468/2/21
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Sanofi breached ABPI Code after uncertified internal email to salesforce about Toujeo patient materi
An anonymous, non-contactable complainant (describing themselves as a Sanofi employee) complained about an email sent to the salesforce titled “Toujeo news – Patient material & Digital camp…
Clauses: NONE
2021 🔒 Subscribe
🔒 Subscribers only
AUTH/3500/4/21
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Employee complaint about representative training at Sanofi (No breach)
An anonymous, non-contactable employee complained about the quality of training provided when joining Sanofi as a diabetes representative.The complainant alleged that much of the training had been …
Clauses: NONE
2021 🔒 Subscribe
🔒 Subscribers only
AUTH/3381/9/20
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Boehringer Ingelheim
A UK health professional complained about a Trajenta (linagliptin) dynamic digital “crawler” banner ad (ref PC-GB-101179) on the Guidelines in Practice website.The banner used headlines includi…
Clauses: NONE
2020 🔒 Subscribe
🔒 Subscribers only
AUTH/3361/6/20
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Anonymous v Merck Sharp & Dohme
An anonymous complainant challenged a Merck Sharp & Dohme (MSD) UK LinkedIn sponsored/targeted post advertising a pharmaceutical promotional meeting on managing type 2 diabetes in patients with…
Clauses: NONE
2020 🔒 Subscribe
🔒 Subscribers only
AUTH/3254/10/19
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Napp breach over BMJ hosted “Invokana” panel
A UK health professional complained that Invokana (canagliflozin) content on a BMJ hosted page appeared promotional and lacked prescribing information and a unique identifier.The material was an �…
Clauses: NONE
2019 🔒 Subscribe
🔒 Subscribers only
AUTH/3252/10/19
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Lilly diabetes website
A UK health professional complained about Lilly’s diabetes website (lillydiabetes.co.uk).The landing page offered two choices: “I am a health professional in the UK” or “I am a patient in t…
Clauses: NONE
2019 🔒 Subscribe
🔒 Subscribers only
AUTH/3185/4/19
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Mundibiopharma breached ABPI Code over Invokana virtual booth email
A UK health professional complained about an email promoting an Invokana (canagliflozin) “virtual booth” linked to ISN-WCN 2019, and the associated microsite content (including slide decks and …
Clauses: NONE
2019 🔒 Subscribe
🔒 Subscribers only
AUTH/3271/10/19
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Napp
A UK health professional complained about Napp’s Invokana (canagliflozin) website, which had a landing page splitting users into a health professional area and a patient/general public area.The c…
Clauses: NONE
2019 🔒 Subscribe
🔒 Subscribers only
AUTH/3133/12/18
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Novo Nordisk breached ABPI Code over missing sponsorship declaration for APPG diabetes summit materi
An anonymous, non-contactable health professional complained about a flyer for an International Diabetes Summit (House of Commons, December 2018) organised by the All Party Parliamentary Group (APP…
Clauses: NONE
2018 🔒 Subscribe
🔒 Subscribers only
AUTH/3034/4/18
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
AstraZeneca ‘Fixing Dad’ HCP webpage ruled promotional in context—missing prescribing information
An anonymous UK health professional complained about a ‘Fixing Dad’ video trailer embedded on AstraZeneca UK’s Medicines website within the diabetes section.The page invited HCPs to arrange a…
Clauses: NONE
2018 🔒 Subscribe
🔒 Subscribers only
AUTH/3071/9/18
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Novo Nordisk
The PMCPA Director initiated a complaint (under Paragraph 5.1 of the Constitution and Procedure) after a BMJ paper (Goldacre et al, 12 Sept 2018) ranked sponsors’ compliance with posting results …
Clauses: NONE
2018 🔒 Subscribe
🔒 Subscribers only
AUTH/3102/9/18
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Lilly
A BMJ paper (Goldacre et al, published online 12 September 2018) assessed whether sponsors posted due clinical trial results to the EU Clinical Trials Register (EUCTR) within the European Commissio…
Clauses: NONE
2018 🔒 Subscribe
🔒 Subscribers only
AUTH/3013/1/18
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
AstraZeneca employee complaint
An anonymous, non-contactable complainant (described as an AstraZeneca UK marketing company employee) alleged AstraZeneca’s global functions did not receive appropriate ABPI Code training and tha…
Clauses: NONE
2018 🔒 Subscribe
🔒 Subscribers only
AUTH/2976/9/17
Social Media & Digital Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
AstraZeneca breached ABPI Code over
A hospital consultant in anaesthesia and intensive care medicine complained about a promotional email for Qtern (saxagliptin/dapagliflozin) sent by AstraZeneca via a third-party professional networ…
Clauses: 9.1,9.2
2017 🔒 Subscribe
🔒 Subscribers only
AUTH/2951/4/17
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Sanofi breached ABPI Code over Toujeo “Latest Data” app implying hypoglycaemia benefit from clamp-st
A consultant physician complained about Sanofi’s promotion of Toujeo (insulin glargine 300U/ml) using a digital “Latest Data” iPad app (ref SAGB.TJO.16.12.1140(1)a, March 2017).The app presen…
Clauses: NONE
2017 🔒 Subscribe
🔒 Subscribers only
AUTH/2906/11/16
Social Media & Digital Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Novo Nordisk
A CMRO paper (ABPI-funded) assessed whether results of company-sponsored trials for EMA-approved 2013 medicines were disclosed within 12 months of the later of first regulatory approval or trial co…
Clauses: NONE
2016 🔒 Subscribe
1 2 Next → Page 1 of 2 — 36 cases
Unlock the Full Case Library
Annual subscription — instant access, cancel anytime.
🏆
The only PMCPA case library of its kind
No other provider publishes a structured, searchable library of PMCPA rulings with video and podcast. A single half-day compliance workshop from a specialist provider typically costs £499+ — for one session. Individual access here is £299 for a full year of 2,000+ cases.
PMCPA Case Library — Team (100 seats)
Custom pricing
tailored to your team size
Bulk pricing available — contact us for a quote
Enquire for bulk pricing →
Individual
For a single learner
£299
per year
Less than a single half-day workshop
  • 1 user seat
  • All 1752+ case studies
  • Video + podcast per case
  • MCQ quiz per case
  • 5 points per case passed
  • New cases added monthly
Create account or sign in to buy
Most Popular
Team 5
Up to 5 team members
£999
per year (£200/seat)
£200/person — the most cost-effective team option
  • 5 user seats
  • All case studies included
  • Video, podcast & MCQ per case
  • Team progress dashboard
  • New cases added monthly
  • Admin management portal
Create account or sign in to buy
Team 25+
25+ team members
Custom pricing
tailored to your team size
Bulk pricing available — contact us for a quote
  • 25 user seats
  • All case studies included
  • Video, podcast & MCQ per case
  • Team progress dashboard
  • Bulk seat management
  • Priority support
Enquire for bulk pricing →

Questions? Email [email protected]  ·  14-day money-back guarantee  ·  Annual subscription, auto-renews